

ANUPAM RASAYAN INDIA LTD.

ARILSLDSTX20231107081	Date: November 07, 2023
То,	То,
BSE Limited,	National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers, Dalal Street,	'Exchange Plaza', C-1, Block-G,
Mumbai -400001, India	Bandra Kurla Complex
SCRIP CODE: 543275	Bandra (East), Mumbai 400051, India
	SYMBOL: ANURAS

Dear Sir/Madam,

Subject: Investor Presentation

Pursuant to Regulation 30 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the 'Investor Presentation' in respect of the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2023, of Anupam Rasayan India Limited (the "*Company*").

The Investor Presentation is also being hosted on the Company's website at <u>www.anupamrasayan.com</u>.

We request you to kindly note the same and take into your records.

Thanking You,

Yours faithfully,

For Anupam Rasayan India Limited


Ashish Gupta Company Secretary and Compliance Officer

Encl.: As above

R ANUPAM RASAYAN INDIA LIMITED

Anupam Rasayan India Limited

Q2 & H1FY24



NOVEMBER 2023

Quarterly Highlights



Quarterly Financial Highlights

Consolidated Total Revenue was **₹3,956 Mn;** Y-o-Y growth of **3.25%**

Standalone Total Revenue was **₹3,206 Mn;** Y-o-Y growth of **3.86%** Consolidated EBITDA (Incl. Other Revenue) was ₹ 1,109 Mn.; margin stands at 28% Consolidated PAT stood at **₹ 487 Mn.**, margin stands at **12%**

Standalone EBITDA (Incl. Other Revenue) was ₹ 947 Mn.; margin stands at 30%

Added **3 new** products in Q2FY24 taking total to **58**

products

Standalone PAT stood at **₹ 387 Mn.**, margin stands at **12%**

Managing Director's Message

"Amidst the challenging external environment, I am happy that we have been able to hold our ground and deliver some growth. Our total revenue for the first half of FY24 reached Rs. 794 crores, reflecting a robust year-over-year growth of 11%. Our strong margins at 28% for H1FY24, are a testament to our unique business model.

During this quarter, we successfully launched three new molecules, bringing the total to five by the end of H1 FY24. We will launch an additional five molecules by the close of FY24. In a bid to balancing our carbon emissions and making significant strides towards achieving energy neutrality by 2027, we have also signed three MoUs with the Government of Gujarat for afforestation.

We are seeing a resurgence in demand, which instills confidence of delivering growth in coming quarters. This bolsters our confidence in achieving consistent growth and maintaining our margin profile. We remain steadfast in our pursuit of growth, sustainability, and contributing positively to the environment."

Mr. Anand S Desai MANAGING DIRECTOR



Operational Updates

Commercialization of New Molecules – In Q2FY24, commercialized **3** new molecules were commercialized taking total to **5** new molecules commercialized in H1FY24, with total of **10** new molecules to be launched in FY24. Of the total 3 molecules, 1 molecule is from fluorination series and 1 molecule is from signed LOIs and contracts.

Capex Incurred – Company incurred capex of **₹2,335 Mn** till Q2FY24 out of the **₹6,700 Mn** announced, with majority of the capex to be incurred as per plan in FY24.

Appointment of CEO – Appointment of Mr. Gopal Agrawal as the CEO of the Company, he has over 25+ years' experience in Corporate Strategy, Global & Domestic M&A, Fund Raise and Management Consulting. He has extensively worked for Indian companies and MNCs across US, Europe and Japan and his core specialization among others has been in Manufacturing and Industrials.

Temporary Increase in Working Capital Cycle – Working Capital cycle of the company increased temporarily on account of increase in debtors due to increase in domestic sales and industry slowdown, however we expect it to normalize in Q3 and Q4FY24.

Consolidated Profit & Loss Summary

(All amounts are in ₹ Mn)	Q2FY24	Q2FY23
INCOME		
Revenue from Operations	3,921	3,928
Other Income	35	(96)
Total Revenue	3,956	3,831
Total Revenue Growth (%)	3%	
EXPENSES:		
Cost of Raw Materials Consumed	1,625	1,617
Gross Profit	2,296	2,311
Gross Margins (%)	59%	59%
Gross Profit growth (%)	(1%)	
Employee Benefits Expenses	185	181
Other Expenses	1,036	1,023
EBITDA (Incl. Other Revenue)	1,109	1,012
EBITDA Margins (%)	28%	26%
EBITDA Growth (%)	10%	
Finance Cost	204	160
Depreciation and Amortization	198	177
Profit Before Tax	707	674
Tax (Including Deferred Tax)	220	196
Profit for the Year	487	478
PAT Margins (%)	12%	12%
PAT Growth (%)	2%	

QUARTERLY FINANCIALS

Standalone Profit & Loss Summary

(All amounts are in ₹ Mn)	Q2FY24	Q2FY23
INCOME		
Revenue from Operations	3,171	3,140
Other Income	35	(53)
Total Revenue	3,206	3,087
Total Revenue Growth (%)	4%	
EXPENSES:		
Cost of Raw Materials Consumed	1,237	1,155
Gross Profit	1,933	1,984
Gross Margins (%)	61%	63%
Gross Profit growth (%)	(3%)	
Employee Benefits Expenses	135	141
Other Expenses	887	893
EBITDA (Incl. Other Revenue)	947	898
EBITDA Margins (%)	30%	29%
EBITDA Growth (%)	6%	
Finance Cost	202	158
Depreciation and Amortization	179	162
Profit Before Tax	566	578
Tax (Including Deferred Tax)	178	166
Profit for the Year	387	412
PAT Margins (%)	12%	13%
PAT Growth (%)	(6%)	

Consolidated Profit & Loss Summary

(All amounts are in ₹ Mn)	H1FY24	H1FY23
INCOME		
Revenue from Operations	7,785	7,299
Other Income	158	(124)
Total Revenue	7,944	7,175
Total Revenue Growth (%)	11%	
EXPENSES:		
Cost of Raw Materials Consumed	3,256	2,993
Gross Profit	4,530	4,306
Gross Margins (%)	58%	59%
Gross Profit growth (%)	5%	
Employee Benefits Expenses	371	324
Other Expenses	2,070	1,953
EBITDA (Incl. Other Revenue)	2,247	1,904
EBITDA Margins (%)	28%	27%
EBITDA Growth (%)	18%	
Finance Cost	382	282
Depreciation and Amortization	385	341
Profit Before Tax	1,480	1,281
Share of profit of associates		15
Tax (Including Deferred Tax)	470	398
Profit for the Year	1,009	898
PAT Margins (%)	13%	13%
PAT Growth (%)	12%	

8

HALF YEARLY FINANCIALS

Standalone Profit & Loss Summary

(All amounts are in ₹ Mn)	H1FY24	H1FY23
INCOME		
Revenue from Operations	6,055	6,238
Other Income	134	(179)
Total Revenue	6,189	6,058
Total Revenue Growth (%)	2%	
EXPENSES:		
Cost of Raw Materials Consumed	2,337	2,284
Gross Profit	3,718	3,954
Gross Margins (%)	61%	63%
Gross Profit growth (%)	(6%)	
Employee Benefits Expenses	271	268
Other Expenses	1,753	1,765
EBITDA (Incl. Other Revenue)	1,828	1,742
EBITDA Margins (%)	30%	29%
EBITDA Growth (%)	5%	
Finance Cost	378	279
Depreciation and Amortization	349	319
Profit Before Tax	1,101	1,144
Tax (Including Deferred Tax)	365	358
Profit for the Year	736	786
PAT Margins (%)	13%	13%
PAT Growth (%)	(6%)	





Innovating Sustainable & Custom Solutions for Global Markets

Company at a glance

Established Custom Synthesis player with **39** years of track record since 1984 Specializes in **multi-step synthesis** undertaking complex chemical reactions Catering to globally relevant chemical & agrochemical companies, including **29 MNC** and cumulative **73** clients Strong supply chain with **backward** integrated facilities

~27,200 MT Manufacturing Capacity, spread over 6 manufacturing facilities Strong technical capabilities in complex chemistries supported by an R&D team of **88** professionals **58** Complex products manufactured as of Q2FY4 consisting of Life science related specialty chemical and other specialty chemical **1,705** + committed employees**Strong and Dedicated** Management Team

Evolution of Anupam

ANUPAM RASAYAN INDIA LTD.

- Fast growing Specialty Chemical Manufacturer with focus on Custom Synthesis.
- Long running relationships with leading MNCs
- Leveraging deep expertise across complex chemistries
- Building platforms across business verticals of Agro, Personal Care, Pharma and Other Specialty Chemicals.

1984 Formed **partnership firm** "Anupam Rasayan"

2006 Started supplying Anti-Bacterial products for **German MNC**

2010

Started supplying to **Syngenta**



Phase I-Inception



2016 Awarded 'Green Innovation Awa

Innovation Award' by Corning Reactor Technology 2017 Started supplying to Sumitomo Japan 2019 Commercialized 2 more manufacturing sites – Unit 5 & 6

Phase II-The Acceleration

2023

- Raised ₹5,000 mn. through QIP
- Commissioned Solar Power Plant of 5.4MW at Bharuch

2022

Acquired ~26% controlling stake in Tanfac Industries Ltd.

2021

•

- Started working with Adama
- Listed on NSE and BSE
- Commissioned Solar Power Plant of 12.5MW at Bharuch

2020

Received DSIR registration for R&D Centre nupam Rasayan India Limited

∢

12

Chemical Conduits and Global Partnerships



13

mited

Note: Financials, revenue from operations proportion rounded-off to zero decimal also *as of FY23.

Charting New Frontiers with R&D Excellence

Process technologies deployed

Flow Chemistry

- Reduced lead time
- Material efficient & cost benefits
- Lesser environmental impacts in the laboratory

Photo Chemistry • Simplified synthesis of



- Larger potential for automation
- novel compounds

complex molecules

Increased access to

Current R&D highlights DSIR recognized R&D center

Team of 88 R&D professionals headed by Dr Nilesh Naik

R&D Capex of **₹55 crores** in last 5 years

New Chemistry Additions

- Balz Schiemann
- Hofmann rearrangement
- Grignard
- Lithiation

- Vilsmeier–Haack
 - Sandmeyer
 - Pyridine Chemistry
 - Vapour Phase & high temperature chlorination



Experienced Leadership & Deep Technical Talent Pool

Experienced management team



Mr. Anand S Desai MANAGING DIRECTOR

Over 30 years of experience in chemicals industry associated with the company since 1992 & was one of the first Directors of the company



Ms. Mona A Desai VICE-CHAIRMAN & WHOLE-TIME DIRECTOR

Over 20 years of experience in chemicals industry and associated with the Board since the incorporation of the company

Mr. Gopal Agrawal

Chief Executive Officer Qualified CA with 25+ yrs. Exp in Corporate Strategy, global M&A and Mgmt Consultancy. Former MD & Head - IB at Edelweiss India

Mr. Amit Khurana Chief Financial Officer Qualified CA with 10+ yrs. exp in taxes/ accounts; Former Head of Indirect Taxes & Costing of co.

Dr. Nileshkumar Naik

Technical Head PhD (Chem), M.Sc. (Organic chemistry); with ARIL since incorporation

Mr. Ravi Desai

Sales Head 20+ years of experience; with ARIL since 2012

Mr. Vishal Thakkar

Deputy CFO 20+ yrs. exp. in M&A, BD, Corporate Finance, with Shell, Essar, GE Capital, Crisil

Dr. Anuj Thakar R&D (Process Development) Head PhD (Chem), M.Sc. (Organic chemistry); with ARIL for 18+ yrs.

Our R&D talent pool

88+ Strength of R&D Team 175+ Strength by

FY24

PhDs in R&D Team

~10% 75+

Chemical Engineers in R&D team

ADDED SENIOR TECHNICAL AND BUSINESS DEVELOPMENT PROFESSIONALS IN FLUORINATION CHEMISTRY, ACROSS R&D, PRODUCTION AND TECHNOLOGY

Expanded Business Development Team Globally

Europe

Mr. Thierry Baumlin Key Account Manager -Crop Protection 30 years+ of experience in Chemicals industry; former strategy procurement head at BASF

Mr. Pierre Joris

Business Advisor -Specialty Fluoro Chemicals 30 years+ of experience in Chemicals industry; former SBU head at Solvay

Japan

Mr. Hiroaki Matsudaira

Director - Business Development - Fluoropolymers & Electronics 20 years + of experience in Chemicals industry; former strategy products head at Mitsubishi

Dr. Hironori Ishikawa

Business Advisor -Electronic Chemicals 20 years+ of experience in chemical industry; previously employed with Mitsubishi Chemical

Mr. Tsutomu Suetomi

Director - Business Development - Crop Protection 30 years+ of experience in Chemicals industry; former Senior sales manager at DuPont

United States

Mr. John Grant

Business Advisor -Specialty Fluoro Chemicals 30 years+ of experience in Chemicals industry; former business development at 3M

Mr. Rob Bryant

Business Advisor -Fluoropolymers 30 years+ of experience in Chemicals industry; Currently working in NASA

Mr. Terry Clair

Business Advisor - Fluoropolymers 30 years+ of experience in Chemicals industry; former employee of NASA

Mr. Victor Hsia

Business Advisor -Electronic Chemicals 20 years+ of experience in Semiconductor industry; former employee of NS Nanotech





Growth Drivers

1

Growth of Product Portfolio



Execution of Signed LOIs and Contracts Expansion in Fluorination chemistry

3

Growth Of Product Portfolio

New Strategic Custom Development Products under pipeline to be manufactured by Anupam in India:

90+

Number of molecules in R&D and Pilot

10+

Number of molecules to be commercialised in FY24



- Established Active Ingredients of originators which are currently being manufactured in Europe and Japan
- Key Intermediates for Newly Launched Active Ingredients



- Import Substitute "Key Starting Materials"; To be manufactured for the first time in India
- Advanced Intermediates


Strong Order Book – Recent LOI/Contracts Signed

Signing Quarter	Segment	Customer	LOI/Contract	Tenor (Years)	Value(₹ Crores)
Q1FY22	Life Science	Multinational Life Science Company	LOI	5	₹1,100
Q1FY22	Life Science	Two Multinational Companies	Contract	5	₹540
Q2FY22	Life Science	European Multinational Company	Contract	5	₹144
Q3FY22	Life Science	Japanese Multinational Company	Contract	4	₹135
Q4FY22	Life Science	Multinational Crop Protection Company	LOI	5	₹700
Q4FY23	Life Science	Japanese Chemical Company	LOI	6	₹984
Q1FY24	Other Specialty Chemical	Japanese Multinational	LOI	7	₹1,500
Q1FY24	Other Specialty Chemical	American Multinational	LOI	5	₹380
Q1FY24	Life Science	Japanese Chemical Company	LOI	5	₹2,186
Total			₹7,669		

LOI/Contracts signed worth ₹7,669 crores in last two years provides strong visibility of revenue for coming years.

Anupam's Strategic Expansion in Fluorination with Tanfac

Anupam acquired ~26% stake in Tanfac for ~₹1,530M in May'22





- Specialty fluoride chemical manufacturer in India
- Leading producer of hydrofluoric acid (HF) and organic and inorganic fluorinebased products
- FY23 revenues of ~₹3,750 Mn



- **Uninterrupted access** to key raw materials (HF and KF) for fluorination chemistry
- Enable future expansion of product series under fluorination chemistry
- Reduce import dependence on China
- Increased capacities of existing product portfolio of Tanfac through process improvement & debottlenecking

Expansion in Fluorination Chemistry

FOCUSED SEGMENTS	MOLECULES	END APPLICATION	CUSTOMER	SEGMENT REVENUE POTENTIAL
	Product A	Elastomer	US MNC	\$ 40 – 70 Mn.
Polymers	Product B	Semiconductor/Flame Retardant	Japanese MNC	
Pharmaceuticals	Product X/Y	Cardio/Anti-viral	Indian MNC	\$ 80 – 90 Mn.
	Product Z	Oncology	Indian MNC	
	Product M	Insecticide	Global MNC	
Agrochem	Product N	Herbicide	European Originator	\$ 100 Mn.

Anupam will source fluorinating agents (KF and HF) from Tanfac and manufacture Value Added Products (VAPs) at Anupam All molecules in these series are high value high margin product For most of this products, Anupam will be single supplier out of Asia on exclusive basis to originators

\$5 + Bn Addressable market of Targeted Series for Anupam*

\$220 – \$260 Mn

Revenue Potential for Anupam*

*Global Consulting Firm Research

Summary

Strengths and Key Highlights

Manufacturing Prowess	 Doubled manufacturing capacity in the last three years Strong capex plans to expand capacity into newer molecules / chemistries
R&D Capabilities	 DSIR recognized R&D center with a team of 88 R&D professionals Strong technical capabilities and robust R&D pipeline (90+ molecules)
Strengthening Supply Chain	 Integration in Customer supply Chain Acquisition of Tanfac for backward integration
Sustainable Business model	 Partner of choice for originators/leading MNC Multi pronged strategy leading to high growth

Corporate Office

Anupam Rasayan India Ltd. India (HQ) 10th Floor, Icon Rio, Dumas Road, Surat, Gujarat, India – 395 007

